Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CTKB
HOLDCytek Biosciences, Inc. · Healthcare · United States · $576M · Avg Vol: $8M/d
COMPANY DESCRIPTION
Cytek Biosciences, Inc. develops and markets proprietary flow cytometry solutions, including instruments, reagents, and software, for cell analysis in research and clinical settings. Its Full Spectrum Profiling (FSP™) technology offers superior multi-parametric analysis with enhanced sensitivity and resolution compared to conventional cytometers, creating a technological advantage. Cytek is a rapidly growing player, disrupting traditional technologies with its innovative platform for deeper cell insights.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.0M | 193.0M | 200.5M | 201.5M | 7.1% | 204.2M | 208.8M | 222.7M | 5.1% |
| EPS | 0.02 | -0.09 | -0.05 | -0.52 | — | -0.57 | — | — | — |
| Shares | 135.4M | 130.7M | 129.2M | 128.6M | -5.0% | 129.1M | — | — | — |
| Debt | 18.1M | 14.1M | 17.0M | 23.7M | 9.5% | 27.5M | — | — | — |
| Equity | 425.3M | 393.1M | 395.7M | 341.7M | -7.0% | — | — | — | — |
| Op CF | -12.2M | 5.3M | 25.4M | -4.7M | 380.6% | -7.3M | — | — | — |
| Inv CF | -55.9M | -93.9M | -83.0M | 10.1M | — | — | — | — | — |
| Fin CF | 5.5M | -41.8M | -15.8M | -13.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CTKB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CTKB | Cytek Biosciences, Inc.(you) | $576M | 40 | HOLD |
| CERS | Cerus Corporation | $587M | 46 | HOLD |
| SIBN | SI-BONE, Inc. | $737M | 42 | HOLD |
| NPCE | NeuroPace, Inc. | $505M | 32 | SELL |
| KIDS | OrthoPediatrics Corp. | $485M | 50 | HOLD |
| OFIX | Orthofix Medical Inc. | $455M | 51 | HOLD |
| QDEL | QuidelOrtho Corporation | $1.1B | 47 | HOLD |
| VREX | Varex Imaging Corporation | $460M | 56 | HOLD |
| CBLL | CeriBell, Inc. | $642M | 22 | SELL |
| TMCI | Treace Medical Concepts, Inc. | $259M | 33 | SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%